A randomized controlled trial of Guben Qushi Huayu Decoction Combined with Shenling Baizhu powder in the treatment of psoriasis with spleen deficiency and dampness obstruction syndrome

Phase 2

Not yet recruiting

• Conditions: psoriasis

• Registration Number: ITMCTR2200005679
• Lead Sponsor: Guangdong Provincial Hospital of Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-02-20

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1.The age is 18-70 years old, both male or female; 2.The patients who meet the diagnostic criteria of stable plaque psoriasis; 3.The degree of skin lesions was moderate (3 = PASI < 10 or 3% = BSA < 10%); 4.The patients who meet the diagnostic criteria of dampness syndrome; 5.Patients with informed consent.

Exclusion Criteria

1.Drip type, reverse type, joint type, pustular type, erythrodermic psoriasis, or psoriasis vulgaris in progressive stage and regression stage. 2.Pregnant or lactating women, or those planning pregnancy within 1 year. 3.Patients with severe primary diseases such as respiratory system, circulatory system, digestive system, endocrine system and urinary system, which can not be controlled by conventional drugs; Patients with severe infection, hepatitis, pulmonary tuberculosis, lymphocyte proliferation, abnormal hematopoietic system and tumor; Patients with severe disorders of water, electrolyte and acid-base balance; Patients with primary or secondary immunodeficiency and hypersensitivity; Or patients whose clinical test indexes belong to one of the following situations: the increase of alanine aminotransferase or aspartate aminotransferase > 1.5 times the upper limit of normal value; The increase of creatinine > 1.5 times the upper limit of normal value; Hemoglobin increase > 20g / L, upper limit of normal value; Thrombocytopenia < 75.0 × 10e9/L Decrease in leukocyte count < 3.0 × 10e9/L The increase of blood potassium is more than 5.5mmol/l or the decrease is less than 3mmol / L, or other abnormal laboratory tests. The researchers judge that it is not suitable for patients to participate in this test. 4.Patients who are known to be allergic to the drugs used in this study and those containing related drug components. 5.Those who are participating in other drug clinical trials or have participated in other clinical trials within 1 month. 6.Patients considered unsuitable for inclusion by the researchers.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified